TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Controlled Study of Olanzapine in Children With Autism
Brief Summary: This is a 12-week study which investigates the use of olanzapine to decrease disruptive behaviors sometimes associated with Autism in children, aged 3 to 12 years old. The first six weeks of the study are double-blind and placebo controlled, meaning that patients receive either placebo or olanzapine, and that neither the researchers nor the patients know whether or not they are receiving placebo or olanzapine. In the second six weeks all of the patients receive olanzapine. The purpose in using placebo is that it is otherwise impossible to know how effective the drug is or whether or not the drug causes side effects. Patients treated with placebo can have improvement and can have side effects. In the study patients receive a psychiatric evaluation, physical examination, laboratory tests, and study medication (olanzapine or placebo), free of charge.


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MPH Trial-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: MPH Trial: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: Med Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Arm Label: MPH Trial: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate-extended release, Drug: Methylphenidate-immediate release | Intervention Type: DRUG; Name: Methylphenidate-extended release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: DRUG; Name: Methylphenidate-immediate release; Assigned to Arm(s): MPH Trial: High Dose, MPH Trial: Low Dose, MPH Trial: Med Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): MPH Trial-Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olanzapine (Zyprexa) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: olanzapine (Zyprexa); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS
Brief Summary: The study will determine whether a daily vitamin and mineral supplement (a multivitamin including Vitamin A) will improve health when added to standard chemotherapy for tuberculosis. This study will compare the effectiveness of the multivitamin in HIV infected and HIV uninfected patients.


Options:
A: Intervention Type: DRUG; Name: multivitamin; Assigned to Arm(s): N/A
B: Arm Label: 7000IU/day; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): 7000IU/day | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: A: tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: B: tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: C: no tenofovir/vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D supplement | Arm Label: D: no tenofovir/placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D supplement; Assigned to Arm(s): A: tenofovir/vitamin D, C: no tenofovir/vitamin D | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): B: tenofovir/placebo, D: no tenofovir/placebo
D: Arm Label: ER niacin followed by ART alone; Type: OTHER; Interventions: Drug: Niacin | Arm Label: ART alone followed by ER niacin; Type: OTHER; Interventions: Drug: Niacin | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): ART alone followed by ER niacin, ER niacin followed by ART alone | Intervention Type: DRUG; Name: Niacin; Assigned to Arm(s): ART alone followed by ER niacin, ER niacin followed by ART alone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adjunct Vitamin A Therapy for Tuberculosis and HIV/AIDS
Brief Summary: The study will determine whether a daily vitamin and mineral supplement (a multivitamin including Vitamin A) will improve health when added to standard chemotherapy for tuberculosis. This study will compare the effectiveness of the multivitamin in HIV infected and HIV uninfected patients.


Options:
A: Intervention Type: DRUG; Name: multivitamin; Assigned to Arm(s): N/A
B: Arm Label: Study drug containing zinc alone; Type: EXPERIMENTAL; Interventions: Drug: Zinc | Arm Label: Study drug Micronutrient without zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient without zinc | Arm Label: Study drug Micronutrient with zinc; Type: EXPERIMENTAL; Interventions: Drug: Micronutrient with zinc | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): Study drug containing zinc alone | Intervention Type: DRUG; Name: Micronutrient without zinc; Assigned to Arm(s): Study drug Micronutrient without zinc | Intervention Type: DRUG; Name: Micronutrient with zinc; Assigned to Arm(s): Study drug Micronutrient with zinc | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Peanuts; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Peanuts | Arm Label: Daboqolo; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Daboqolo | Intervention Type: DIETARY_SUPPLEMENT; Name: Peanuts; Assigned to Arm(s): Peanuts | Intervention Type: DIETARY_SUPPLEMENT; Name: Daboqolo; Assigned to Arm(s): Daboqolo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Vitamin D | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D, Drug: Placebo L-arginine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: L-arginine, Drug: Placebo Vitamin D | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo L-arginine, Drug: Placebo Vitamin D | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo L-arginine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Placebo Vitamin D; Assigned to Arm(s): 3, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CBASP Augmentation for Treatment of Chronic Depression
Brief Summary: This 24-week study, with a 12-month follow up period, will compare the effectiveness of antidepressant medication alone to the combination of psychotherapy and antidepressant medication in patients with chronic depression.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: organized care program for chronic or recurrent depression | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: organized care program for chronic or recurrent depression; Assigned to Arm(s): Intervention Group
C: Arm Label: CBASP; Type: EXPERIMENTAL; Interventions: Behavioral: CBASP | Arm Label: Brief Supportive Psychotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Brief Supportive Psychotherapy | Arm Label: Medication Only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Medication Only | Intervention Type: BEHAVIORAL; Name: Brief Supportive Psychotherapy; Assigned to Arm(s): Brief Supportive Psychotherapy | Intervention Type: BEHAVIORAL; Name: CBASP; Assigned to Arm(s): CBASP | Intervention Type: DRUG; Name: Medication Only; Assigned to Arm(s): Medication Only
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Recurrence in Depression With Drugs and CT
Brief Summary: This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.


Options:
A: Arm Label: Supported Protocolized Discontinuation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD) | Arm Label: SPD + Mindfulness (MBCT); Type: EXPERIMENTAL; Interventions: Behavioral: Supported Protocolized Discontinuation (SPD), Behavioral: Mindfulness Based Cognitive Therapy (MBCT) | Intervention Type: BEHAVIORAL; Name: Supported Protocolized Discontinuation (SPD); Assigned to Arm(s): SPD + Mindfulness (MBCT), Supported Protocolized Discontinuation | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy (MBCT); Assigned to Arm(s): SPD + Mindfulness (MBCT)
B: Intervention Type: DRUG; Name: Venlafaxine ER; Assigned to Arm(s): N/A
C: Arm Label: CBT/Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram, Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: No CBT/escitalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram | Arm Label: CBT/placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Cognitive behavioral therapy (CBT) | Arm Label: No CBT/placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): CBT/Escitalopram, No CBT/escitalopram | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CBT/placebo, No CBT/placebo | Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): CBT/Escitalopram, CBT/placebo
D: Arm Label: Cognitive therapy plus medications; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Therapy, Drug: Medications | Arm Label: Medications alone; Type: EXPERIMENTAL; Interventions: Drug: Medications | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): Cognitive therapy plus medications | Intervention Type: DRUG; Name: Medications; Assigned to Arm(s): Cognitive therapy plus medications, Medications alone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outreach and Treatment for Depression in the Labor Force
Brief Summary: This study will assess the effects of depression treatment on employee productivity. This study will also evaluate the impact of depression screening and outreach on employees' receptivity to treatment.


Options:
A: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A
B: Arm Label: Structured patient visits; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Arm Label: Treatment as usual; Type: OTHER; Interventions: Behavioral: Structured patient-centered follow up of depression | Intervention Type: BEHAVIORAL; Name: Structured patient-centered follow up of depression; Assigned to Arm(s): Structured patient visits, Treatment as usual
C: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A
D: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outreach and Treatment for Depression in the Labor Force
Brief Summary: This study will assess the effects of depression treatment on employee productivity. This study will also evaluate the impact of depression screening and outreach on employees' receptivity to treatment.


Options:
A: Arm Label: TCSCT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Arm Label: Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Telepsychiatry-based Culturally Sensitive Collaborative Treatment | Intervention Type: BEHAVIORAL; Name: Telepsychiatry-based Culturally Sensitive Collaborative Treatment; Assigned to Arm(s): TCSCT, Usual Care
B: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A
C: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telemedicine intervention | Intervention Type: BEHAVIORAL; Name: Telemedicine intervention; Assigned to Arm(s): Arm 1
D: Intervention Type: PROCEDURE; Name: management of therapy complications; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: pain therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Outreach and Treatment for Depression in the Labor Force
Brief Summary: This study will assess the effects of depression treatment on employee productivity. This study will also evaluate the impact of depression screening and outreach on employees' receptivity to treatment.


Options:
A: Arm Label: Tailored Physical Activity; Type: EXPERIMENTAL; Interventions: Other: Tailored Physical Activity | Arm Label: Reference group; Type: OTHER; Interventions: Behavioral: Health Counselling | Intervention Type: OTHER; Name: Tailored Physical Activity; Assigned to Arm(s): Tailored Physical Activity | Intervention Type: BEHAVIORAL; Name: Health Counselling; Assigned to Arm(s): Reference group
B: Arm Label: long rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: long rehabilitation program | Arm Label: short rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: short rehabilitation program | Arm Label: Acceptance and commitment therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Acceptance and commitment therapy (ACT) | Arm Label: Untouched; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: long rehabilitation program; Assigned to Arm(s): long rehabilitation | Intervention Type: BEHAVIORAL; Name: short rehabilitation program; Assigned to Arm(s): short rehabilitation | Intervention Type: BEHAVIORAL; Name: Acceptance and commitment therapy (ACT); Assigned to Arm(s): Acceptance and commitment therapy
C: Intervention Type: BEHAVIORAL; Name: Care manager outreach and monitoring; Assigned to Arm(s): N/A
D: Arm Label: Workplace dialogue; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Workplace dialogue | Arm Label: Care as usual; Type: SHAM_COMPARATOR; Interventions: Other: Care as usual | Intervention Type: BEHAVIORAL; Name: Workplace dialogue; Assigned to Arm(s): Workplace dialogue | Intervention Type: OTHER; Name: Care as usual; Assigned to Arm(s): Care as usual

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Early Age Mania (TEAM) Study
Brief Summary: This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: lithium plus carbamazepine; Type: EXPERIMENTAL; Interventions: Drug: lithium plus carbamazepine | Arm Label: lithium plus valproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: lithium plus valproate | Intervention Type: DRUG; Name: lithium plus carbamazepine; Assigned to Arm(s): lithium plus carbamazepine | Intervention Type: DRUG; Name: lithium plus valproate; Assigned to Arm(s): lithium plus valproate
C: Arm Label: Lithium (LI); Type: EXPERIMENTAL; Interventions: Drug: Lithium (LI) | Arm Label: Divalproex (DV); Type: EXPERIMENTAL; Interventions: Drug: Divalproex (DV) | Intervention Type: DRUG; Name: Lithium (LI); Assigned to Arm(s): Lithium (LI) | Intervention Type: DRUG; Name: Divalproex (DV); Assigned to Arm(s): Divalproex (DV)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Lithium carbonate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Valproate | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Lithium carbonate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Valproate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Trial of Combination Anastrozole (NSC #719344) Plus ZD1839 (Iressa, NSC #715055, IND #61187) and of Combination Fulvestrant (NSC #719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer
Brief Summary: This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast cancer. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen. Gefitinib (ZD1839) may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether gefitinib is more effective when combined with anastrozole or fulvestrant in treating breast cancer.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant, Drug: anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: fulvestrant | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: exemestane | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: exemestane; Assigned to Arm(s): 3
B: Arm Label: Arm I (anastrozole, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: gefitinib, Other: laboratory biomarker analysis | Arm Label: Arm II (fulvestrant, gefitinib); Type: EXPERIMENTAL; Interventions: Drug: gefitinib, Drug: fulvestrant, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I (anastrozole, gefitinib) | Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib) | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II (fulvestrant, gefitinib) | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I (anastrozole, gefitinib), Arm II (fulvestrant, gefitinib)
C: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: anastrozole | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: anastrozole, Drug: fulvestrant | Intervention Type: DRUG; Name: anastrozole; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: fulvestrant; Assigned to Arm(s): Arm II
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anastrozole | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fulvestrant, Drug: Anastrozole | Intervention Type: DRUG; Name: Fulvestrant; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Anastrozole; Assigned to Arm(s): 1, 2

Answer: B